Elevation Oncology Inc
NASDAQ:ELEV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Metallurgical Corporation of China Ltd
SSE:601618
|
CN |
|
O
|
OM Holdings Ltd
ASX:OMH
|
SG |
Elevation Oncology Inc
Total Current Liabilities
Elevation Oncology Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elevation Oncology Inc
NASDAQ:ELEV
|
Total Current Liabilities
$4.5m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Total Current Liabilities
$641.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
37%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
Elevation Oncology Inc
Glance View
Elevation Oncology, Inc. operates as a precision oncology company. The company is headquartered in New York City, New York and currently employs 35 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. Its lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1 (NRG1) fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The firm's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.
See Also
What is Elevation Oncology Inc's Total Current Liabilities?
Total Current Liabilities
4.5m
USD
Based on the financial report for Dec 31, 2024, Elevation Oncology Inc's Total Current Liabilities amounts to 4.5m USD.
What is Elevation Oncology Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
49%
Over the last year, the Total Current Liabilities growth was 8%. The average annual Total Current Liabilities growth rates for Elevation Oncology Inc have been -20% over the past three years , 49% over the past five years .
